BioHarvest Sciences (BHST) Competitors $6.91 -0.14 (-1.99%) As of 11:47 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock BHST vs. CGEM, KMDA, RGNX, RZLT, TRML, MBX, FULC, ERAS, PRTC, and TERNShould you be buying BioHarvest Sciences stock or one of its competitors? The main competitors of BioHarvest Sciences include Cullinan Therapeutics (CGEM), Kamada (KMDA), REGENXBIO (RGNX), Rezolute (RZLT), Tourmaline Bio (TRML), MBX Biosciences (MBX), Fulcrum Therapeutics (FULC), Erasca (ERAS), PureTech Health (PRTC), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry. BioHarvest Sciences vs. Its Competitors Cullinan Therapeutics Kamada REGENXBIO Rezolute Tourmaline Bio MBX Biosciences Fulcrum Therapeutics Erasca PureTech Health Terns Pharmaceuticals BioHarvest Sciences (NASDAQ:BHST) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation. Do analysts recommend BHST or CGEM? BioHarvest Sciences presently has a consensus price target of $13.67, indicating a potential upside of 97.78%. Cullinan Therapeutics has a consensus price target of $30.00, indicating a potential upside of 286.10%. Given Cullinan Therapeutics' higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than BioHarvest Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioHarvest Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer BHST or CGEM? In the previous week, Cullinan Therapeutics had 2 more articles in the media than BioHarvest Sciences. MarketBeat recorded 2 mentions for Cullinan Therapeutics and 0 mentions for BioHarvest Sciences. Cullinan Therapeutics' average media sentiment score of 0.94 beat BioHarvest Sciences' score of 0.93 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment BioHarvest Sciences Positive Cullinan Therapeutics Positive Is BHST or CGEM more profitable? Cullinan Therapeutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -31.30%. Cullinan Therapeutics' return on equity of -29.47% beat BioHarvest Sciences' return on equity.Company Net Margins Return on Equity Return on Assets BioHarvest Sciences-31.30% -307.04% -33.21% Cullinan Therapeutics N/A -29.47%-28.19% Which has better earnings & valuation, BHST or CGEM? BioHarvest Sciences has higher revenue and earnings than Cullinan Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioHarvest Sciences$25.19M4.50-$12.91M-$0.50-13.82Cullinan TherapeuticsN/AN/A-$167.38M-$2.91-2.67 Which has more volatility and risk, BHST or CGEM? BioHarvest Sciences has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Do insiders & institutionals believe in BHST or CGEM? 86.3% of Cullinan Therapeutics shares are held by institutional investors. 7.2% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryCullinan Therapeutics beats BioHarvest Sciences on 9 of the 13 factors compared between the two stocks. Get BioHarvest Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for BHST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BHST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BHST vs. The Competition Export to ExcelMetricBioHarvest SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$115.80M$2.93B$5.50B$9.38BDividend YieldN/A2.46%4.25%4.06%P/E RatioN/A20.3128.1019.86Price / Sales4.50183.28380.1579.06Price / CashN/A42.3835.5357.53Price / Book86.387.838.265.72Net Income-$12.91M-$55.11M$3.24B$257.80M7 Day Performance-4.29%2.18%0.50%1.07%1 Month Performance-0.86%12.98%7.99%11.31%1 Year PerformanceN/A1.98%28.68%17.01% BioHarvest Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BHSTBioHarvest SciencesN/A$6.91-2.0%$13.67+97.8%N/A$115.80M$25.19M0.00N/ACGEMCullinan Therapeutics1.7427 of 5 stars$7.70-1.8%$30.00+289.6%-59.8%$462.67MN/A-2.6530KMDAKamada4.3164 of 5 stars$7.75-3.4%$13.00+67.7%+29.9%$461.19M$160.95M26.72360Positive NewsRGNXREGENXBIO4.0392 of 5 stars$8.68-4.2%$31.63+264.3%-37.3%$454.45M$83.33M-2.79370RZLTRezolute2.4162 of 5 stars$5.26+0.2%$11.83+125.0%+11.9%$448.98MN/A-4.5740TRMLTourmaline Bio2.0016 of 5 stars$17.98+3.5%$49.33+174.4%+16.0%$446.16MN/A-5.6044News CoveragePositive NewsMBXMBX Biosciences2.3593 of 5 stars$13.04+5.2%$37.50+187.6%N/A$435.85MN/A0.0036News CoveragePositive NewsAnalyst ForecastHigh Trading VolumeFULCFulcrum Therapeutics0.5964 of 5 stars$7.83-2.2%$6.29-19.7%-9.0%$432.37M$80M-111.84100ERASErasca2.9668 of 5 stars$1.45-4.6%$4.57+215.3%-55.4%$430.60MN/A-2.34120Positive NewsPRTCPureTech Health2.4847 of 5 stars$17.60-1.8%$45.00+155.7%-19.9%$430.42M$4.83M0.00100News CoverageTERNTerns Pharmaceuticals3.7627 of 5 stars$4.90+0.6%$15.63+218.9%-45.7%$425.33MN/A-4.5040 Related Companies and Tools Related Companies Cullinan Therapeutics Competitors Kamada Competitors REGENXBIO Competitors Rezolute Competitors Tourmaline Bio Competitors MBX Biosciences Competitors Fulcrum Therapeutics Competitors Erasca Competitors PureTech Health Competitors Terns Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BHST) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioHarvest Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioHarvest Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
